Evaluation of efficacy on pigmentation by R1110 using In vivo confocal laser microscopy.

Evaluation of efficacy on pigmentation by R1110 using In vivo confocal laser microscopy. - Evaluation of efficacy on pigmentation by R1110.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005379

Enrollment

Registered

2011-04-13

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solar lentigo or melasma

Interventions

Melasma:After face washing, apply the cosmetics to the whole face by usual methods, and apply the test product to the study area (1), twice a day (morning and evening).Then, if necessary, other beauty

12 weeks. Melasma:After face washing, apply the cosmetics to the whole face by usual methods, and apply the test product to the study area (2), twice a day (morning and evening).Then, if necessary, ot

12 weeks. Solar lentigo:After face washing, apply the cosmetics to the whole face by usual methods, and apply the test product to the study area, twice a day (morning and evening).Then, if necessary,

12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 years old or more than it at the date the informed consent was taken on. 2) Subjects with solar lentigo or melasma. 3) Subjects who have the compliance for study protocol. 4) Subjects who signed the informed consent forms approved by the ethical board of the study institution.

Exclusion criteria

Exclusion criteria: 1) Subjects who used hydroquinone products or retinoic acid products (concentration: more than 0.1%) within the past 3 months. 2) Subjects who used the internal medicine containing tranexamic acid or L- cysteine or vitamin C or E within the past 3 months. 3) Subjects who underwent the plastic treatment or the beauty salon treatment within the past 2 months. 4) Subjects who used the quasi drugs or the cosmetic products (e.g. the products containing vitamin C or arbutin, etc. Except for hydroquinone) for whitening within the past 1 month from informed consent. 5) Subjects who underwent the hormone complement treatment within the past 1 month. 6) Subjects who are exposed to the severe ultraviolet rays of the sun. 7) Subjects with severe diseases, e.g. hepatic disease and renal disease. 8) Subjects with allergy or atopic dermatitis, and a history of contact dermatitis. 9) Females who are pregnant or breast feeding, and females of childbearing potential. 10) Subjects who are considered ineligible by the principal or other investigators.

Design outcomes

Primary

Measure	Time frame
-Melanin index -Degree of skin tone color scale -Observation of internal skin by in vivo confocal laser microscopy -Skin symptom score (safety)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026